Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.56 |
| ▸ | DRD1 | P21728 | 10/20 | 0.56 |
| ▸ | DRD4 | P21917 | 7/20 | 0.55 |
| ▸ | DRD5 | P21918 | 8/20 | 0.50 |
| ▸ | DRD3 | P35462 | 8/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468509 | 0.93 | DRD2 (0.55) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5040462 | 0.93 | DRD2 (0.55) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL22469630 | 0.82 | PARP10 (0.57) | PARP1PARP10TDP2F7F3 | |
| SCHEMBL23561875 | 0.81 | TDP2 (0.44) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1264716 | 0.80 | PARP10 (0.59) | PARP1PARP10TDP2F7F3 | |
| SCHEMBL2061223 | 0.79 | CA9 (0.46) | PARP1PARP10TDP2F7F3 | |
| SCHEMBL29051697 | 0.78 | ALDH1A1 (0.54) | PARP1PARP10TDP2 | |
| SCHEMBL5334289 | 0.75 | PARP10 (0.57) | PARP1PARP10TDP2F7F3 | |
| SCHEMBL2061125 | 0.75 | PARP10 (0.53) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5044544 | 0.75 | DRD2 (0.53) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| CN-116332910-A | 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof | 江苏威凯尔医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-01 | — | — | US | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| EP-1680127-B1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070117791-A1 | Bicyclic compounds | JOLIDON SYNESE | 2007-05-24 | — | — | US | disclosed |
| US-7173023-B2 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1680127-A1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| US-20050107360-A1 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005039591-A1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107360-A1 | Bicyclic compounds | MAOB, MAOA, XDH | DRD2 71/4885DRD1 182/4885DRD4 139/4885 |
| US-20070117791-A1 | Bicyclic compounds | MAOB, MAOA, XDH | DRD2 71/4885DRD1 179/4885DRD4 150/4885 |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | BACE1, BACE2, BCHE | DRD2 1589/4885DRD1 2004/4885DRD4 1956/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | DRD2 1589/4885DRD1 2004/4885DRD4 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.